Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENGI-003
- Development stage
- Preclinical
- Lead developer
- Engimmune Therapeutics
01
Overview
ENGI-003 is a soluble T-cell receptor (TCR) drug candidate being developed by Engimmune Therapeutics for the treatment of solid tumors. The drug is part of Engimmune's pipeline, which focuses on identifying and selecting TCRs that can target and eliminate cancer cells. Engimmune Therapeutics is collaborating with the Swiss Technology Innovation Center CSEM to accelerate the safety screening of its TCRs, aiming to de-risk development by identifying and ruling out potentially toxic candidates early in the process. The partnership is supported by a grant from Innosuisse, the Swiss Innovation Agency. Engimmune Therapeutics is a 2021 spin-off from ETH Zurich.
02
Targets
CD3 (T-cell surface glycoprotein CD3)GPC3 (Glypican-3)
Beyond the preview
Go deeper on ENGI-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENGI-003.